title: microRNA-202-3p inhibits cell proliferation by targeting ADP-ribosylation factor-like 5A in human colorectal carcinoma.
abstract: OBJECTIVE
  MicroRNAs (miRNA) that are strongly implicated in carcinogenesis have recently reshaped our understanding of the role of non-protein-coding RNAs. Here, we focused on the function and molecular mechanism of miR-202-3p and its potential clinical application in colorectal cancer.
  
  
  METHODS
  miR-202-3p expression was determined by quantitative reverse transcriptase PCR (qRT-PCR) in 94 colorectal cancer tissues and corresponding noncancerous tissues (NCT). Cell proliferation and colony formation assays in vitro and xenograft experiments in vivo were used to evaluate the effect of miR-202-3p on colorectal cancer cell proliferation. Luciferase assay and Western blot analysis were performed to validate the potential targets of miR-202-3p after the preliminary screening by online prediction and microarray analysis. The mRNA and protein levels of target genes were detected by qRT-PCR and immunohistochemical staining. The copy number of pre-miR-202 was measured by quantitative PCR.
  
  
  RESULTS
  First, miR-202-3p was significantly downregulated in 46.7% colorectal cancer samples compared with NCTs. The overexpression of miR-202-3p inhibited colorectal cancer cell growth in vitro and repressed tumorigenesis in nude mice. Then, miR-202-3p downregulated ADP-ribosylation factor-like 5A (ARL5A) protein level by binding to its 3' untranslated region, and knockdown of ARL5A phenocopied the proliferation inhibition effect of miR-202-3p. Furthermore, both of ARL5A mRNA and protein levels were upregulated in colorectal cancer samples compared with NCTs and high ARL5A protein levels predicted a poor prognosis.
  
  
  CONCLUSIONS
  miR-202-3p might function as a tumor suppressor in colorectal cancer, and ARL5A, the functional target of miR-202-3p in colorectal cancer, is a potential prognostic factor for colorectal cancer.
authors: Authors' Affiliations: Department of Pathology; bioMérieux Laboratory, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College; Institute of Pathology; Institutes of Biomedical Sciences, Fudan University, Shanghai; Wuxi Oncology Institute, the Affiliated Hospital of Jiangnan University, Wuxi; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine; and Department of Oncology, Ren Ji Hospital, Shanghai Jiao Tong University, Shanghai, China.
authors: Qifeng
authors: Q
authors: Wang
authors: Zhaohui
authors: Z
authors: Huang
authors: Weijie
authors: W
authors: Guo
authors: Shujuan
authors: S
authors: Ni
authors: Xiuying
authors: X
authors: Xiao
authors: Lisha
authors: L
authors: Wang
authors: Dan
authors: D
authors: Huang
authors: Cong
authors: C
authors: Tan
authors: Qinghua
authors: Q
authors: Xu
authors: Ruopeng
authors: R
authors: Zha
authors: Jiwei
authors: J
authors: Zhang
authors: Weiqi
authors: W
authors: Sheng
authors: Xianghuo
authors: X
authors: He
authors: Xiang
authors: X
authors: Du
mesh_terms: D020727:ADP-Ribosylation Factors / Q000235:genetics*; D000818:Animals; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D004195:Disease Models, Animal; D015536:Down-Regulation; D015870:Gene Expression; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D051379:Mice; D035683:MicroRNAs / Q000235:genetics*; D011379:Prognosis; D034622:RNA Interference; D023041:Xenograft Model Antitumor Assays
chemical_list: C569392:MIRN202 microRNA, human; D035683:MicroRNAs; D020727:ADP-Ribosylation Factors; C475879:ARL5A protein, human